國家衛生研究院 NHRI:Item 3990099045/4903
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912822      Online Users : 1191
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4903


    Title: Bacteremia due to extended-spectrum-beta-lactamase-producing enterobacter cloacae: Role of carbapenem therapy
    Other Titles: Bacteremia due to extended-spectrum-β-lactamase-producing enterobacter cloacae: role of carbapenem therapy
    Authors: Lee, CC;Lee, NY;Yan, JJ;Lee, HC;Chen, PL;Chang, CM;Wu, CJ;Ko, NY;Wang, LR;Chi, CH;Ko, WC
    Contributors: Division of Infectious Diseases
    Abstract: Enterobacter cloacae is one of important nosocomial pathogens. However, few studies specifically dealing with clinical characteristics and outcome of extended-spectrum beta-lactamase (ESBL)-producing E. cloacae infections have been published. During an eight-year period in a medical center, of 610 E. cloacae bacteremic isolates, 138 (22.6 %) with ESBL genes were designated as the ESBL group; and 120 (19.6 %) with cefotaxime-nonsusceptible without ESBL phenotype and genes as the control group. Of the former isolates, 133 (96.3%) had blaSHV-12, three (2.1%) blaCTX-M3, and two (1.4%) both blaSHV-12 and blaCTX-M3. After exclusion of age <18 year, there were 206 adults with E. cloacae bacteremia, 121 patients in the ESBL group and 85 in the control group. More episodes of hospital-onset and polymicrobial bacteremia, increased severity of illness, more bacteremic onset in intensive care units (ICUs), and longer stay in the hospital and ICU after bacteremic onset, were noted in the ESBL group. However, the crude and sepsis-related mortality rates in two groups were similar. Of the ESBL group, the in-hospital sepsis-related mortality rate of patients definitively treated by a carbapenem was lower than that of those by non-carbapenem ss-lactams (5/53, 9.4% vs. 13/44, 29.5%; P=0.01), though the difference was not significant in the hierarchical multivariate analysis (P=0.46). Among 62 patients with follow-up blood cultures within 14 days of bacteremic onset, breakthrough bacteremia was more common in those treated by a non-carbapenem beta-lactam agent than those treated by a carbapenem (18/31, 58.0% vs. 3/31, 9.6%; P<0.001). Thus, carbapenem therapy for ESBL-producing E. cloacae bacteremia may provide therapeutic benefits.
    Date: 2010-09
    Relation: Antimicrobial Agents and Chemotherapy. 2010 Sep;54(9):3551-3556.
    Link to: http://dx.doi.org/10.1128/aac.00055-10
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000281005900003
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77956129671
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB20547798.pdf314KbAdobe PDF846View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback